人脐静脉内皮细胞分泌组织型纤溶酶原激活物及其抑制剂1对醒脑静干预的反应

背景：前期研究发现醒脑静能有效抑制兔心肌缺血再灌注模型的炎症递质及促纤溶作用,但是影响纤溶系统活性的作用机制未完全明确。目的：观察醒脑静对重组人肿瘤坏死因子α介导人脐静脉内皮细胞分泌组织型纤溶酶原激活物和纤溶酶原激活物抑制剂1及其基因表达的影响。方法：取3-5 代人脐静脉内皮细胞,在培养基中添加10 μg/L 重组人肿瘤坏死因子α介导人脐静脉内皮细胞分泌组织型纤溶酶原激活物和纤溶酶原激活物抑制剂1及其基因表达,醒脑静组加入不同浓度(5,10,20 mL/L)的醒脑静干预,阳性对照组添加氟伐他汀(1 μmol/L),并设立单纯人脐静脉内皮细胞培养的空白对照组。培育24 h后采用酶联免疫吸附双抗体夹心法(ELISA)检测细胞上清液组织型纤溶酶原激活物和纤溶酶原激活物抑制剂1水平;采用反转录聚合酶链反应检测人脐静脉内皮细胞的组织型纤溶酶原激活物和纤溶酶原激活物抑制剂1的mRNA表达。结果与结论：重组人肿瘤坏死因子α组纤溶酶原激活物抑制剂1分泌和mRNA表达较空白对照组显著升高 (P < 0.05),组织型纤溶酶原激活物分泌和mRNA表达较空白对照组显著降低(P < 0.05)。不同浓度醒脑静组纤溶酶原激活物抑制剂1分泌和mRNA表达均较重组人肿瘤坏死因子α组显著降低(P < 0.05),而组织型纤溶酶原激活物分泌和mRNA表达均较重组人肿瘤坏死因子α组显著升高(P < 0.05),且呈剂量依赖关系。结果证实,醒脑静作用可逆转重组人肿瘤坏死因子α所致的人脐静脉内皮细胞的纤溶活性。 中国组织工程研究杂志出版内容重点：组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程全文链接：     

遗传和环境因素对高血压病患者血浆纤溶酶原活化剂抑制 …

目的 探讨纤维酶在化剂抑制物－１（ＰＡＩ－１）基因启动子区４Ｇ／５Ｇ多态性,以及环境因素对高血压病患者血浆ＰＡＩ－１水平的影响,方法 随机收集２４０例高血压病患者（男１２０例,女１２０例,年龄３３－８９岁,平均６５岁）,血浆ＰＡＩ－１抗原由ＥＬＩＳＡ法测得,ＰＡＩ－１ ４Ｇ／５Ｇ基因型分析采用等位基因特异性寡核苷酸探针点杂交方法。结果 血浆ＰＡＩ－１水平与ＰＡＩ－１ ４Ｇ／５Ｇ多态性明显在,４Ｇ／     

甲基强的松龙对狼疮性肾炎患者血浆中PAI-1的影响

目的 :研究甲基强的松龙对Ⅳ型狼疮性肾炎 (LN)患者血浆中 1型纤溶酶原激活物抑制物 (PAI 1)的影响。方法 :应用免疫组织化学ELISA方法检测患者血浆中PAI 1含量。结果 :①LN治疗组与对照组比较 (P <0 0 1) ;②LN患者经甲基强的松龙两次冲击治疗后与治疗前分别比较 (P <0 .0 1) ;③甲基强的松龙第二次冲击治疗后 ,与对照组比较无显著性差异 (P >0 0 5 )。结论 :甲基强的松龙通过干扰纤溶酶原激活物 (PA) 纤溶酶系统 ,使LN病人血浆中PAI 1含量明显降低 ,从而发挥治疗作用。     

Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women

OBJECTIVE:

The development of osteoporosis is associated with several risk factors, such as genetic structures that affect bone turnover and bone mass. The impact of genetic structures on osteoporosis is not known. Plasminogen activator inhibitor type-1 regulates the bone matrix and bone balance. This study assessed the correlation between plasminogen activator inhibitor type-1 gene 4G/5G polymorphisms and osteoporosis in a population of Turkish women.

METHODS:

A total of 195 postmenopausal female patients who were diagnosed with osteoporosis (Group I) based on bone mineral density measurements via dual-energy x-ray absorptiometry and 90 females with no osteoporosis (Group II) were included in this study. Correlations between PAI-1 gene 4G/5G polymorphisms and osteoporosis were investigated through the identification of PAI-1 gene 4G/5G polymorphism genotypes using the polymerase chain reaction.

RESULTS:

No significant differences in the genotype and allele frequency of 4G/5G plasminogen activator inhibitor type-1 polymorphisms were observed between the two groups, and both groups exhibited the most frequently observed 4G5G genotype.

CONCLUSION:

No correlation between the development of osteoporosis in the female Turkish population and 4G/5G plasminogen activator inhibitor type-1 gene polymorphisms was observed.     

Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 levels in acute myocardial infarction

The cause of the circadian variation in the incidence of acute myocardial infarction (AMI) has not been identified. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) have opposing effects on thrombi. Hence, the extent of the clot, the size of the infarct and outcome of patients could depend on t-PA and PAI-1 levels. In an effort to elucidate the pathophysiologic basis of circadian variation of AMI, we investigated the presence of a possible corresponding circadian variation in the levels of endogenous t-PA and PAI-1 in patients diagnosed to have AMI and the effects of hypertension, diabetes and site of the infarct on these levels. We estimated the levels of t-PA and PAI-1 in platelet-poor plasma of 42 patients with AMI on admission, using the enzyme-linked immunosorbant assay. Although not statistically significant, patients having an AMI in the morning hours had the highest t-PA:PAI-1 ratio. The normal circadian variation in PAI-1 levels was lost in patients with AMI, probably due to the disease process. Also, the t-PA levels in hypertensive patients were significantly lower than in nonhypertensives. PAI-1 levels were also significantly lower in patients with anteroseptal than in inferior and anterolateral AMI. This relationship between the fibrinolytic potential and the site of infarction needs further study. Furthermore, t-PA levels on admission were significantly lower in survivors and may have a predictive value in determining the outcome.     

人脑星形细胞瘤纤溶酶原激活抑制因子1基因表达研究

目的研究人脑星形细胞瘤纤溶酶原激活抑制因子１（ＰＡＩ１）基因表达及其临床意义。方法采用Ｎｏｒｔｈｅｒｎ杂交和免疫组化ＡＢＣ方法检测３６例人脑星形细胞瘤ＰＡＩ１ｍＲＮＡ和蛋白表达，分析其与临床病理因素之间的关系。结果所有星形细胞瘤组织均可表达３．０ｋｂ和２．２ｋｂ的ＰＡＩ１ｍＲＮＡ转录物；高分级星形细胞瘤ＰＡＩ１ｍＲＮＡ表达水平显著高于低分级星形细胞瘤（Ｐ＜００１）；正常脑组织未检测出ＰＡＩ１ｍＲＮＡ表达。ＰＡＩ１ｍＲＮＡ表达水平与星形细胞瘤的坏死（ｒ＝０．５１，Ｐ＜０．０１）、微血管数（ｒ＝０．３３，Ｐ＜０．０１）及脑水肿（ｒ＝０．２７，Ｐ＜０．０１）呈显著正相关，与患者性别、年龄及瘤体大小无显著相关性。免疫组化染色显示，ＰＡＩ１蛋白主要分布在高分级星形细胞瘤的瘤细胞和内皮细胞，尤以血管增殖部位和坏死灶周围较为显著，低分级星形细胞瘤呈低水平表达。结论ＰＡＩ１基因表达与人脑星形细胞瘤的分级、坏死、血管生成及脑水肿密切相关，可作为星形细胞瘤恶性程度的分子标记。     

纤溶酶原激活物抑制剂1 siRNA对大鼠肺纤维化的治疗作用

 目的： 观察纤溶酶原激活物抑制剂1 （PAI-1）siRNA对博来霉素(BLM)诱导的大鼠肺纤维化的治疗作用,并初步探讨其机制。方法： 72只Wister大鼠分为4组,即对照组（control组）、BLM组、BLM+非特异 siRNA 组(BLM+N组)和BLM+PAI-1 siRNA组(BLM+P组)。BLM 5 mg/kg气管内滴入制作肺纤维化模型,control组注入等体积的生理盐水。造模后,于局麻下BLM+P组每周2次气管内注入PAI-1 siRNA 7.5 nmol (0.2 mL);BLM+N组注入相同剂量的非特异siRNA;control组和BLM组注入等体积的生理盐水,28 d共给药8次。分别于第7 d、14 d和28 d每组处死6只,左肺行肺泡灌洗测定PAI-1活性,右中叶肺组织RT-PCR法检测Ⅲ型胶原、α-平滑肌肌动蛋白（α-SMA）和金属蛋白酶组织抑制物1（TIMP-1）的mRNA表达。结果： 造模后,7 d、14 d和28 d肺泡灌洗液中PAI-1活性持续升高,每周2次气管内注入PAI-1 siRNA可以使肺泡灌洗液中PAI-1的活性降低,与同一时点BLM组比较有明显差异（均P<0.05）;模型组7 d、14 d和28 d  Ⅲ型胶原、α-SMA和TIMP-1的mRNA表达明显增高,BLM+P组3个时点Ⅲ型胶原、α-SMA和TIMP-1的mRNA表达明显减少,分别与同一时点BLM组比较有明显差异（均P<0.05）。结论： 每周2次气管内给予PAI-1 siRNA可以持续减少PAI-1表达。PAI-1 siRNA不但直接抑制肺纤维化进展,而且可以打破基质金属蛋白酶及组织抑制因子之间的平衡。     

Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile

Fibrinolytic properties have been detected in animal and human gallbladder (GB) bile. Plasminogen activator inhibitor-1 (PAI-1) has been reported in greater concentration in GB stone bile and may be a nucleating factor in the pathogenesis of GB stone formation. It is unknown whether or not human choledochal bile has similar properties, which could have a role in choledocholithiasis. The aims of this study were to determine the presence of fibrinolytic properties of human choledochal bile and to compare those properties among normal, acalculous, and calculous-infected choledochal bile. Tissue plasminogen activator (t-PA) and PAI-1 of choledochal bile were measured by enzyme linked immunosorbent assay in patients with cholangitis due to acalculous bile duct obstructions (n = 9), choledocholithiasis with cholangitis (n = 20), and normal bile (n = 7). The t-PA concentration of choledochal bile was no different among the three groups (acalculous-infected bile, median 4.61 ng/ml, and calculous-infected bile, 4.61 ng/ml, versus normal bile, 7.33 ng/ml). PAI-1 was detected in choledochal bile in significantly greater concentrations in patients with acalculous cholangitis due to bile duct obstructions and choledocholithiasis with cholangitis (acalculous-infected bile, median 0.36 ng/ml, and calculous-infected bile, 0.1 ng/ml, versus normal bile, 0.02 ng/ml, p < 0.05), but the bile concentration of PAI-1 was no different between the acalculous and calculous-infected choledochal bile. Human choledochal bile possesses t-PA and PAI-1. PAI-1 was present in greater concentrations in both acalculous and calculous-infected choledochal bile. Increased levels of PAI-1 may be an epiphenomenon of cholangitis rather than a factor in the pathogenesis of choledocholithiasis.     

胰岛素和葡萄糖对缺氧血管内皮细胞分泌tPA和PAI-1抗原的影响

目的: 观察胰岛素和葡萄糖对缺氧血管内皮细胞分泌组织型纤溶酶原激活物(tPA)及其抑制物-1(PAI-1)的影响。 方法:培养人脐静脉内皮细胞株ECV-304。分组实验:(1)常氧组;(2)在缺氧条件下又分为Ⅰ:缺氧对照组;Ⅱ:低浓度组:胰岛素150 mU/L、葡萄糖5.5 mmol/L;Ⅲ:中浓度组:胰岛素450 mU/L、葡萄糖15 mmol/L;Ⅳ:高浓度组:胰岛素900 mU/L、葡萄糖30 mmol/L;Ⅴ:渗透压对照组:甘露醇24.5 mmol/L。取培养4、8、12 h 3个时点,用ELISA法测定细胞培养上清液tPA、PAI-1抗原。结果:缺氧明显增加tPA和PAI-1抗原分泌,tPA/PAI-1值明显增加(P＜0.01)。胰岛素和葡萄糖能够刺激缺氧内皮细胞分泌tPA和PAI-1抗原,在缺氧8 h以内,tPA/PAI-1比值明显增加(P＜0.05)。随缺氧时间的延长,tPA/PAI-1值逐渐下降。结论:胰岛素和葡萄糖能够刺激内皮细胞分泌tPA和PAI-1抗原,在缺氧8 h以内,tPA/PAI-1值升高,纤溶活性升高,有利于局部自发性纤溶的发生。此作用可能是IGK治疗急性心肌梗死的机制之一。     

不饱和脂肪酸影响HepG-2细胞PAI-1表达的机制初探

目的：探讨不饱和脂肪酸对HepG-2细胞纤溶酶原激活物抑制剂-1(PAI-1)表达的影响及其机制。方法： 以发色底物法检测PAI-1活性，RT-PCR法检测PAI-1 mRNA水平；构建两个含不同片段缺失的PAI-1启动子序列控制表达的氯霉素转移乙酰酶（CAT）报告基因质粒，转染HepG-2细胞，ELISA法检测CAT表达量。结果： 油酸、亚油酸诱导下HepG-2细胞PAI-1mRNA表达及蛋白活性显著高于对照组；共转染过氧化体增殖物激活型受体表达质粒（PPARα-pSG5）PAI-1转录活性显著增加；转染NF-κB样蛋白结合序列缺失的重组质粒，亚油酸诱导下PAI-1转录活性显著增加，而转染VLDL/脂肪酸反应元件缺失的重组质粒则无显著变化。结论： 不饱和脂肪酸增强HepG-2细胞PAI-1 mRNA表达及活性；PPARα可能是其上调PAI-1表达所涉及的转录因子之一，且VLDL/脂肪酸反应元件在该调控中具有重要作用，但可能并不涉及NF-κB信号转导途径。     

mmLDL对人脐静脉内皮细胞PAI-1表达的影响及其转录调控机制

目的:探讨弱氧化修饰低密度脂蛋白(mmLDL)对人脐静脉内皮细胞(HUVEC)PAI-1活性和mRNA表达的影响及其转录调控机制。方法:人脐静脉内皮细胞的培养和鉴定。用发色底物法测定PAI-1活性。Northern印迹分析法检测PAI-1mRNA的水平。采用基因重组技术构建含不同长度PAI-1 5'上游序列的荧光素酶报告基因质粒, 瞬时转染进入内皮细胞, 并检测荧光素酶的表达情况。 利用PCR和测序技术, 对构建质粒上AP-1元件进行定点突变。Western blot印迹杂交检测内皮细胞核内激活蛋白-1(AP-1)蛋白水平。结果:50 mg/L mmLDL诱导HUVECs PAI-1活性和mRNA表达量明显增高, 同时提高核内AP-1蛋白水平。mmLDL显著诱导构建质粒pGL3-PAI-1-1509/+90和pGL3-PAI-1-823/+90的荧光素酶活性, 但对质粒pGL3-PAI-1-553/+90和pGL3-PAI-1-47/+90诱导作用不明显。当PAI-1 5'上游序列的3个AP-1元件突变后, mmLDL的诱导作用明显降低。结论:(1)mmLDL增强血管内皮细胞 PAI-1活性与mRNA表达;(2)PAI-1活性提高与其mRNA表达增加呈正相关;(3) PAI－1 5'上游序列中3个AP-1元件在mmLDL对PAI－1诱导中具有重要调控作用。     

PAI-1在多囊卵巢综合征大鼠脂肪组织中的表达及意义

目的 探讨纤溶酶原激活物抑制因子-l(PAI-1)在多囊卵巢及正常大鼠脂肪组织中的表达及在多囊卵巢综合征(PCOS)发病中的作用.方法 应用脱氢表雄酮(DHEA)皮下注射23 d龄SD雌性大鼠20天,建立PcOS大鼠模型,应用免疫组织化学技术对PAI-1在大鼠脂肪组织的表达强度变化进行研究.结果 PCOS大鼠模型建立成功;PAI-1在PCOS组脂肪组织基质细胞上的表达明显增强.结论 PAI-1在多囊卵巢大鼠发病中起着重要作用.     

The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia

Preeclampsia is associated with thrombosis of the intervillous or spiral artery. A deletion/insertion polymorphism (4G or 5G) in the promoter of the plasminogen activator inhibitor type 1 (PAI-1) gene is suggested to be involved in regulating the synthesis of the inhibitor, 4G allele, being associated with the enhanced gene expression and plasma PAI-1 levels. We assessed the association between preeclampsia and the 4G/5G polymorphism of the PAI-1 gene in 115 preeclamptic patients, 210 pregnant controls, and 298 healthy volunteer controls. The frequency of the homozygotes for the 4G allele was significantly higher in the patients than in the control pregnant women (P = 0.04) or in the healthy volunteers (P = 0.02). The 4G allele frequency was also significantly higher in the patients than in the control group of pregnant women (P = 0.03) and in the healthy volunteers (P = 0.02). These results suggest that the presence of the 4G/4G genotype of the PAI-1 gene is one of the risk factors for preeclampsia. Received: October 14, 1999 / Accepted: January 4, 2000     

Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer

Expression of urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2) was evaluated in 125 surgically resected gastric cancers by immunohistochemical analysis. Tissue was stained immunohistochemically with a monoclonal antibody against human uPA and monoclonal antibodies against human PAI-1 and PAI-2. In addition, DNA ploidy patterns were determined by cytofluorometer after staining with propidium iodide. We found that 82 (66%) of the 125 gastric cancers expressed uPA as diffuse cytoplasmic staining, as intensely outlined luminal borders. PAI-1 expression was observed in 62 (50%) of 125 gastric cancer as a fine, diffuse and granular pattern in the cytoplasm. PAI-2 expression was observed in 65 (52%) of the 125 gastric cancers as a diffuse cytoplasmic staining. uPA-positive tumours showed a higher incidence of infiltration, lymph node metastasis and peritoneal dissemination than uPA-negative ones. Patients with uPA-positive tumours proved to have a significantly poorer prognosis than those with negative ones. PAI-1-negative tumours showed a higher incidence of liver metastasis and carried a poorer prognosis than PAI-1-positive ones. There was no significant correlation between uPA or PAI-1 expression and DNA ploidy patterns. Conversely, there was no significant relationship between PAI-2 expression and clinicopathological parameters and prognosis. According to the expression of uPA and PAI-1 status, groups of 19 uPA(–)/PAI-1(–), 44 uPA(+)/PAI-1(–), 23 uPA(–)/PAI-1(+) and 39 uPA(+)/PAI-1(+) were subdivided. Tumours with UPA(+)/PAI-1(–) had a significantly higher incidence of liver metastasis, lymph node metastasis and serosal invasion than the other groups of tumours. Patients with uPA(+)/PAI-1(–) tumours had a significantly poorer prognosis than those with uPA(–)/PAI-1(+) tumours. These results indicate that uPA expression is a useful biological prognostic indicator, and that uPA and PAI-1 may play an important part in the tumour progression and metastasis in gastric cancer.     

PAI-1基因4G/5G多态性与特发性肺纤维化的相关性研究

目的探讨纤溶酶原激活剂抑制物-1（plasminogen activator inhibitor-1,PAI-1）基因启动子区4G/5G多态性与特发性肺纤维化（IPF）的相关性。方法应用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）分析,检测42例IPF患者和164例正常对照组人群PAI-1基因4G/5G多态性。结果PAI-1基因4G/4G、4G/5G、5G/5G基因型频率分布,IPF组分别为31.0%、50.0%、19.0%,对照组分别为17.1%、54.9%、28.0%;4G和5G等位基因频率,IPF组分别为0.560和0.440,对照组分别为0.445和0.555;4G/4G基因型频率IPF组显著高于对照组（P〈0.05）。与4G/5G和5G/5G基因型比较,携带4G/4G型个体发生IPF的风险增加2.18倍,95%CI：1.02～4.68（P〈0.05）。结论PAI-1基因4G/5G多态性与IPF的发病相关,纯合子4G/4G基因型可能是IPF发病的重要危险因素之一。     

Diagnostic and Therapeutic Approach for Acute Paraquat Intoxication

Paraquat (PQ) has known negative human health effects, but continues to be commonly used worldwide as a herbicide. Our clinical data shows that the main prognostic factor is the time required to achieve a negative urine dithionite test. Patient survival is a 100% when the area affected by ground glass opacity is <20% of the total lung volume on high-resolution computed tomography imaging 7 days post-PQ ingestion. The incidence of acute kidney injury is approximately 50%. The average serum creatinine level reaches its peak around 5 days post-ingestion, and usually normalizes within 3 weeks. We obtain two connecting lines from the highest PQ level for the survivors and the lowest PQ level among the non-survivors at a given time. Patients with a PQ level between these two lines are considered treatable. The following treatment modalities are recommended to preserve kidney function: 1) extracorporeal elimination, 2) intravenous antioxidant administration, 3) diuresis with a fluid, and 4) cytotoxic drugs. In conclusion, this review provides a general overview on the diagnostic procedure and treatment modality of acute PQ intoxication, while focusing on our clinical experience.     

糖基化终末产物对大鼠肾系膜细胞纤溶酶原激活物抑制物-1表达的影响

目的:观察糖基化终末产物(AGEs)对大鼠肾系膜细胞纤溶酶原激活物抑制物-1(PAI-1)表达的影响及其与细胞外基质(ECM)成分含量的关系。方法:体外培养正常大鼠肾系膜细胞,分别用糖化牛血清白蛋白(AGEs)及未经糖化的牛血清白蛋白(BSA)处理,以常规培养的肾系膜细胞作为对照,检测不同时间、不同浓度AGEs对纤维连接蛋白(FN)、Ⅳ型胶原、PAI-1表达的影响。MTT法检测AGEs对系膜细胞增殖的作用,ELISA测定条件培养基中FN、Ⅳ型胶原及PAI-1蛋白含量,逆转录聚合酶链式反应(RT-PCR)检测系膜细胞PAI-1mRNA的表达。结果:与相应浓度的BSA比较,AGEs(0-200mg/L)对系膜细胞增殖无明显影响,但可不同程度地刺激系膜细胞FN、Ⅳ型胶原、PAI-1蛋白的产生。RT-PCR检测显示,给予AGEs(100mg/L)的系膜细胞PAI-1mRNA的表达明显增加(P<0.01)。结论:AGEs促进系膜细胞PAI-1的表达,提示AGEs通过上调PAI-1的表达而减少细胞外基质降解,可能是糖尿病肾病细胞外基质积聚的原因之一。     

糖基化终末产物对大鼠肾系膜细胞纤溶酶原激活物抑制物-1表达韵影响

目的：观察糖基化终末产物（AGEs）对大鼠肾系膜细胞纤溶酶原激活物抑制物-1（PAI-1）表达的影响及其与细胞外基质（ECM）成分含量的关系。方法：体外培养正常大鼠肾系膜细胞，分别用糖化牛血清白蛋白（AGEs）及未经糖化的牛血清白蛋白（BSA）处理，以常规培养的肾系膜细胞作为对照，检测不同时间、不同浓度AGEs对纤维连接蛋白（FN）、Ⅳ型胶原、PAI-1表达的影响。MTT法检测AGEs对系膜细胞增殖的作用，ELISA测定条件培养基中FN、Ⅳ型胶原及PAI-1蛋白含量，逆转录聚合酶链式反应（RT—PCR）检测系膜细胞PAI-1 mRNA的表达。结果：与相应浓度的BSA比较，AGEs（0—200mg／L）对系膜细胞增殖无明显影响，但可不同程度地刺激系膜细胞FN、Ⅳ型胶原、PAI-1蛋白的产生。RT—PCR检测显示，给予AGEs（100mg／L）的系膜细胞PAI-1 mRNA的表达明显增加（P〈0．01）。结论：AGEs促进系膜细胞PAI—1的表达，提示AGEs通过上调PAI-1的表达而减少细胞外基质降解，可能是糖尿病肾病细胞外基质积聚的原因之一。